pSivida Announces Two Tech Evaluation Agreements with Leading Global Pharmaceutical Company
May 12 2015 - 7:30AM
Business Wire
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing
sustained release, drug delivery products for treating eye
diseases, today announced that it has signed two funded technology
evaluation agreements with a leading global pharmaceutical company.
The agreements will each evaluate the use of pSivida’s Durasert™
technology to deliver a specific compound to treat a significant
ophthalmic disease.
“We are very pleased to be working with this leading global
pharmaceutical company,” said Dr. Paul Ashton, president and CEO of
pSivida. “Our strategy includes partnering product development with
market leaders in appropriate circumstances, allowing us to expand
our reach beyond our own product development. This opportunity fits
that criteria, and we are excited about the potential
products.”
About pSivida Corp.
pSivida Corp. (www.psivida.com) headquartered in Watertown, MA,
is a leader in the development of sustained release, drug delivery
products for treating eye diseases. pSivida developed three of only
four back of the eye implants approved by the FDA (Vitrasert® and
Retisert®, licensed to Bausch & Lomb; and ILUVIEN®, licensed to
Alimera Sciences). pSivida’s lead product candidate, Medidur™ for
the treatment of posterior uveitis, is currently in pivotal phase
III clinical trials. pSivida is also involved in the development of
products focused on ocular and systemic delivery of biologics and
drugs to treat wet and dry age-related macular degeneration (AMD),
glaucoma, osteoarthritis and other diseases. These products are in
preclinical development utilizing pSivida’s two core technology
platforms: Durasert™ and/or Tethadur™.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION
REFORM ACT OF 1995: Various statements made in this release are
forward-looking, and are inherently subject to risks, uncertainties
and potentially inaccurate assumptions. All statements that address
activities, events or developments that we intend, expect or
believe may occur in the future are forward-looking statements.
These forward looking statements include, but are not limited to,
statements regarding the regulatory path to obtain regulatory
approval of Medidur in the United States, the benefit we may
receive from our share of net profits on sales of ILUVIEN, the
timing of the filing of an NDA for Medidur, FDA’s willingness to
accept the NDA, the timing of results of our phase III trial of
Medidur, and the length of time our capital resources will last and
be sufficient to fund our planned development programs. Some of the
factors that could cause actual results to differ materially from
the anticipated results or other expectations expressed,
anticipated or implied in our forward-looking statements include
uncertainties with respect to: ability to achieve profitable
operations and access to capital; fluctuations in operating
results; further impairment of intangible assets; decline in
Retisert royalties; successful commercialization of, and receipt of
revenues from, ILUVIEN for DME; effect of pricing and reimbursement
decisions on sales of ILUVIEN for DME; consequences of fluocinolone
acetonide side effects; number and cost of clinical trials and data
necessary to support an NDA for, approval by Indian regulators of
the trial design for, timing of filing the NDA for, and regulatory
approval and successful commercialization of, Medidur; delays in
completion of clinical trials; increases in cost of clinical
trials; changes in, or misunderstandings with respect to, FDA
guidance on required clinical trials; development of the
Latanoprost Product and any exercise by Pfizer of its option;
ability of Tethadur to successfully deliver large biologic
molecules and to develop products using it; ability to successfully
develop product candidates, complete clinical trials and receive
regulatory approvals; ability to market and sell products; success
of current and future license agreements; termination of license
agreements; effects of competition and other developments affecting
sales of products; market acceptance of products; effects of
guidelines, recommendations and studies; protection of intellectual
property and avoiding intellectual property infringement; retention
of key personnel; product liability; industry consolidation;
compliance with environmental laws; manufacturing risks; risks and
costs of international business operations; legislative or
regulatory changes; volatility of stock price; possible dilution;
absence of dividends; and other factors described in our filings
with the SEC. You should read and interpret any forward-looking
statements together with these risks. Should known or unknown risks
materialize, or should underlying assumptions prove inaccurate,
actual results could differ materially from past results and those
anticipated, estimated or projected in the forward-looking
statements. You should bear this in mind as you consider any
forward-looking statements. Our forward-looking statements speak
only as of the dates on which they are made. We do not undertake
any obligation to publicly update or revise our forward-looking
statements even if experience or future changes makes it clear that
any projected results expressed or implied in such statements will
not be realized.
Follow pSivida on social media:
Twitter: https://twitter.com/pSividaCorp
Facebook:
https://www.facebook.com/pages/PSivida-Corp/544893792199562
LinkedIn: http://www.linkedin.com/company/psivida
Google+:
https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts
The President's Blog:
http://www.thechairmansblog.com/paul-ashton
For more information on pSivida, visit www.psivida.com.
Martin E. Janis & Company, Inc.Beverly JedynakPresident+1
312 943 1123M: +1 773 350 5793bjedynak@janispr.com
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Psivida Corp (ASX:PVA)
Historical Stock Chart
From Jul 2023 to Jul 2024